Tilman Schlothauer

This inventor holds 36 USPTO granted patents and 28 published patent applications, plus 4 CIPO patents and 23 EPO patents, primarily in Bispecific Antibodies. Top assignees: Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ag, Roche Glycart Ag. Active years: 2015-2026.

USPTO Granted Patents = 36 (Patent Applications = 28)

% Patents Active = 91.7

CIPO Patents = 4 (Patent Applications = 16)

EPO Patents = 23 (Patent Applications = 42)

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 208(Granted Patents)

Location History:

Penzberg, GB (2019)
Penzberg, DE (2015 - 2023)

Company Filing History:

33 out of 5,011

Hoffmann-La Roche Inc.

patents

1 out of 180

F. Hoffmann-La Roche Ag

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Affinity Chromatography

Fc-region Variants

Anti-Transferrin Receptor

Humanized Antibodies

Fc-receptor Binding

Protein A-binding

In Vivo Half-life

Complement Factor

PD1 and TIM3

Anti-Tau Antibodies

Targeted Integration

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723069 - Modification of Antibody FcRn binding (2026-09-01),

2. 12637506 - FC-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE (2026-05-26),

3. 12630622 - BISPECIFIC ANTI-CCL2 ANTIBODIES (2026-05-19),

4. 12596120 - PH-gradient SPR-based binding assay (2026-04-07),

5. 12522637 - COMPLEMENT FACTOR BASED AFFINITY CHROMATOGRAPHY (2026-01-13),

6. 12466872 - METHOD FOR THE GENERATION OF AN FCRN EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION (2025-11-11),

7. 12461109 - Vitro prediction of in vivo half-life (2025-11-04),

8. 12398203 - Method for producing bispecific antibodies comprising a Y436A Fc-region mutation for improved protein A-binding (2025-08-26),

9. 12391757 - Bispecific antibodies specific for PD1 and TIM3 (2025-08-19),

10. 12297263 - Humanized anti-Tau(PS422) antibodies and methods of use (2025-05-13),

11. 12264196 - Fc-receptor binding modified asymmetric antibodies and methods of use (2025-04-01),

12. 12252533 - Anti-transferrin receptor antibodies with tailored affinity (2025-03-18),

13. 12215152 - Humanized anti-human CD19 antibodies and methods of use (2025-02-04),

14. 12103967 - Bispecific anti-CCL2 antibodies (2024-10-01),

15. 11814409 - Fc-receptor based affinity chromatography (2023-11-14),

Title: **Tilman Schlothauer: Innovator in Antibody Development**

Introduction

Tilman Schlothauer, located in Penzberg, Germany, is a notable inventor with an impressive portfolio of 24 patents. His work primarily focuses on the development of antibodies and their therapeutic applications, showcasing his commitment to advancing medical science.

Latest Patents

Among his latest patents, Tilman has developed humanized anti-human CD19 antibodies, which specifically bind to the human CD19 protein. This antibody incorporates several hypervariable regions (HVR), each comprising distinct amino acid sequences that enhance its functionality. In another significant innovation, he has produced bispecific anti-CCL2 antibodies that target two different epitopes on human CCL2, offering potential treatments for cancers, inflammatory, autoimmune, and ophthalmologic diseases.

Career Highlights

Tilman has made significant contributions during his tenure at Hoffmann-La Roche Inc. and Roche Glycart AG. His work at these renowned companies has led to groundbreaking discoveries and advancements in antibody-based therapies, solidifying his reputation in the field of biomedicine.

Collaborations

In his journey, Tilman has collaborated with distinguished colleagues, including Ekkehard Moessner and Guy Georges. These partnerships have enriched his research, fostering innovation and enhancing the development of effective therapeutic solutions.

Conclusion

Tilman Schlothauer's extensive experience and innovative approach to antibody development demonstrate his pivotal role in the biotechnology sector. With his continued dedication to research and collaboration, he remains a key figure in the advancement of medical therapeutics, with a bright future ahead.